Clarendon Private LLC Lowers Stock Holdings in Thermo Fisher Scientific Inc. $TMO

Clarendon Private LLC reduced its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 5.3% in the 2nd quarter, HoldingsChannel reports. The institutional investor owned 798 shares of the medical research company’s stock after selling 45 shares during the period. Clarendon Private LLC’s holdings in Thermo Fisher Scientific were worth $324,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. GW Henssler & Associates Ltd. boosted its holdings in Thermo Fisher Scientific by 0.9% in the second quarter. GW Henssler & Associates Ltd. now owns 37,057 shares of the medical research company’s stock valued at $15,025,000 after purchasing an additional 347 shares during the period. Mitchell Sinkler & Starr PA boosted its holdings in Thermo Fisher Scientific by 11.3% in the second quarter. Mitchell Sinkler & Starr PA now owns 692 shares of the medical research company’s stock valued at $281,000 after purchasing an additional 70 shares during the period. Criteria Caixa S.A.U. purchased a new position in Thermo Fisher Scientific in the second quarter valued at $6,171,000. Legal Advantage Investments Inc. boosted its holdings in Thermo Fisher Scientific by 1.2% in the second quarter. Legal Advantage Investments Inc. now owns 8,329 shares of the medical research company’s stock valued at $3,377,000 after purchasing an additional 100 shares during the period. Finally, Lawson Kroeker Investment Management Inc. NE boosted its holdings in Thermo Fisher Scientific by 0.8% in the second quarter. Lawson Kroeker Investment Management Inc. NE now owns 15,626 shares of the medical research company’s stock valued at $6,336,000 after purchasing an additional 123 shares during the period. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms recently issued reports on TMO. UBS Group lifted their target price on Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a “neutral” rating in a report on Thursday, July 24th. Wells Fargo & Company decreased their target price on Thermo Fisher Scientific from $570.00 to $565.00 and set an “overweight” rating for the company in a report on Thursday, July 24th. Royal Bank Of Canada set a $561.00 price target on Thermo Fisher Scientific and gave the stock an “outperform” rating in a report on Tuesday, September 2nd. HSBC reaffirmed a “hold” rating and set a $510.00 price target on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Finally, JPMorgan Chase & Co. lifted their price target on Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an “overweight” rating in a report on Thursday. Sixteen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $593.43.

Insider Transactions at Thermo Fisher Scientific

In related news, CAO Joseph R. Holmes sold 385 shares of the business’s stock in a transaction dated Friday, August 29th. The stock was sold at an average price of $492.63, for a total value of $189,662.55. Following the transaction, the chief accounting officer owned 2,319 shares in the company, valued at $1,142,408.97. The trade was a 14.24% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Gianluca Pettiti sold 400 shares of the business’s stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $479.98, for a total value of $191,992.00. Following the completion of the transaction, the executive vice president owned 22,367 shares in the company, valued at $10,735,712.66. This trade represents a 1.76% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 30,066 shares of company stock worth $14,182,963. Corporate insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Stock Down 1.8%

TMO opened at $524.95 on Friday. The business’s 50-day simple moving average is $488.68 and its 200-day simple moving average is $447.94. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $610.97. The stock has a market capitalization of $198.23 billion, a P/E ratio of 30.36, a price-to-earnings-growth ratio of 2.85 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, topping analysts’ consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The business had revenue of $10.86 billion for the quarter, compared to analysts’ expectations of $10.68 billion. During the same quarter in the previous year, the firm earned $5.37 earnings per share. The business’s revenue was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.